- Lung cancer
Charu Aggarwal, MD, MPH
About me
- Physician Leader, Airways Malignancies Research
- Director, Precision Oncology Innovation, Penn Center for Cancer Care Innovation
- Section Chief, Head & Neck and Thoracic Cancers, Hematology-Oncology
- Leslye M. Heisler Professor for Lung Cancer Excellence
Dr. Aggarwal specializes in the management of patients with lung cancer. Her clinical research focus is on the development of novel immunotherapeutic approaches, and the discovery and application of biomarkers to guide therapy and monitor treatment. She serves as the local and national principal investigator for multiple clinical trials focusing on the development of targeted immunotherapy approaches.
My education and training
- Medical School: Lady Hardinge Medical College
- Residency: Buffalo General Medical Center
- Fellowship: Fox Chase Cancer Center
Spoken languages
Reviews
206 reviews
Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.
Insurance accepted
- Aetna Advantra Cares D-SNP
- Aetna Advantra Credit Value
- Aetna Advantra Eagle HMO
- Aetna Advantra Eagle POS
- Aetna Advantra Premier Plus PPO
- Aetna Advantra Value
- Aetna Advantra Value Plus
- Aetna APCN Plus (Multi-Tier)
- Aetna Better Health Kids (CHIP) - DH Only
- Aetna Flexible Five
- Aetna Freedom Core
- Aetna Gold
- Aetna HMO
- Aetna Philly Prime
- Aetna POS
- Aetna PPO APCN
- Aetna Premier
- Aetna Premier Plus
- Aetna Savings Plus
- Aetna Signature Administrators
- Aetna Student Health Plan PPO
- Aetna Upfront Advantage
- First Health HMO
- First Health POS
- First Health PPO
- Meritain - Aramark (Other)
- Meritain - Aramark (Pennsylvania Premier Medical Plan)
- Americhealth Caritas of PA VIP - LGH Only
- Amerihealth Caritas (Transplant patients only)
- Amerihealth Caritas of PA - LGH Only
- Centivo EPO
- Cigna Healthcare EPO
- Cigna Healthcare HMO
- Cigna Healthcare POS
- Cigna Healthcare PPO
- Claim Watcher (Homestead/ INDECs) Open Access
- Clover Health Choice
- Clover Health Choice Value PPO
- Clover Health Classic HMO
- Clover Health Value
Locations
Penn Medicine hospital privileges
- Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Qualifications and experience
- Medical Oncology, 2011
- American Society of Clinical Oncology (ASCO), National
- Eastern Cooperative Oncology Group, National
- European Society of Medical Oncology, International
- International Association for the Study of Lung Cancer, International
- Penn Center for Head and Neck Cancer
- Penn Lung Cancer Program
Treatments and conditions
Research
Publications
Adam Barsouk, Maxim Yaskolko, Jonathan H. Sussman, Lova Sun, Roger B. Cohen, Charu Aggarwal, Corey J. Langer, Melina E. Marmarelis Sotorasib vs adagrasib in the 2L+ setting: Outcomes in a large, multi-institutional, real-world database of KRAS-G12C mutated mNSCLC. , J Clin Oncol: 2026
Lova Sun, Willdragon Wang, Kyle Chang, Leslie A. Bucheit, Keelia Clemens, Aditi P. Singh, Melina E. Marmarelis, Roger B. Cohen, Corey J. Langer, Charu Aggarwal Long-term ctDNA reassessment (LTctDNA) in NSCLC immunotherapy responders. , J Clin Oncol: 2026
Melina E. Marmarelis, Jessica Dow, Journey Penney, Binyam Yilma, Alexis Aiello, Marina Codari, Chithra Sangli, Karen Huelsman, Andrew J. Parchman, Charu Aggarwal, Sarah G. Thompson, Natraj R. Ammakkanavar, George R. Simon, Amol Rao, Gautum Agarwal, Ezra E. Cohen, Jyoti D. Patel, Noah Zimmerman Multi-center prospective study evaluating an AI-enabled clinical decision support tool to improve biomarker testing in early-stage NSCLC. , J Clin Oncol: 2026
Adam Barsouk, Jonathan H. Sussman, Maxim Yaskolko, Lova Sun, Aditi P. Singh, Charu Aggarwal, Roger B. Cohen, Melina E. Marmarelis, Corey J. Langer Performance status and tarlatamab outcomes in a large, multi-institution real-world database of 2L+ ES-SCLC. , J Clin Oncol: 2026
Teja Voruganti, Yi Lian, Benjamin A. Bleiberg, Lauren Reed-Guy, Roger B. Cohen, David J. Cantor, Kyle W. Robinson, Christopher D'Avella, Christine A. Ciunci, Melina E. Marmarelis, Aditi P. Singh, Corey J. Langer, Lova Sun, Charu Aggarwal SPARK-Lung: A study of patterns and outcomes in young-onset lung cancer , J Clin Oncol: 2026
Klein M, Watson D, Castro M, Kapoor S, Nair PR, Rajagopalan S, Qin H, Glaser M, Westanmo A, Lala DA, Kumar A, Chauhan J, G P, Ullal YS, Kulkarni S, Narvekar Y, Ghosh A, Tyagi A, Patil M, Macpherson MD, Wingrove JA, Patil T, Aggarwal C, Ganti AK. Use of an Integrative Genomics Approach to Identify Metastatic NSCLC Patients Benefiting From the Addition of Chemotherapy to Immune Checkpoint Inhibitors , Clin Lung Cancer: 2026
Phurin Areesawangkit, Adam Barsouk, Maxim Yaskolko, Lucy Wang, Cole Friedes, Roger B. Cohen, Lova Sun, Charu Aggarwal, Melina E. Marmarelis, Aditi P. Singh, Kyle W. Robinson, Christopher D'Avella, Christine A. Ciunci, Steven J. Feigenberg, Jeffrey D. Bradley, Nikhil Yegya-Raman, Michelle Iocolano, Christiana Davis, Corey J. Langer Long-term survival outcomes of consolidative local ablative therapy after response to first-line systemic treatment in oligometastatic NSCLC. , J Clin Oncol: 2026
Michelle A. Worst, Andrew Small, Amy Furedy, Charu Aggarwal, Sandip P. Patel The impact of online CME on addressing clinical decision-making for immunotherapy in advanced squamous NSCLC. , J Clin Oncol: 2026
Xavier Orcutt, Vivek Nimgaonkar, Lova Sun, Charu Aggarwal, Aaron B. Cohen, Ronac Mamtani, Qi Long, Ravi B. Parikh Machine learning risk stratification in a US-based database to identify subgroups of patients with PD-L1-high NSCLC who benefit from adding chemotherapy to pembrolizumab. , J Clin Oncol: 2026
Rachel Jaber Chehayeb, Willdragon Wang, Lova Sun, Aditi P. Singh, Roger B. Cohen, Corey J. Langer, Charu Aggarwal, Melina E. Marmarelis Incidentally discovered lung cancer in explanted lungs at the time of lung transplantation: Management and outcomes. , J Clin Oncol: 2026